尿路上皮癌
成纤维细胞生长因子受体
癌症研究
癌症
医学
膀胱癌
内科学
成纤维细胞生长因子
受体
作者
Kriti Mittal,Monika Joshi
出处
期刊:Med
[Elsevier]
日期:2024-03-01
卷期号:5 (3): 176-178
标识
DOI:10.1016/j.medj.2023.12.008
摘要
As frontline treatment of advanced urothelial cancer (UC) evolves, optimal sequencing of subsequent therapies remains unclear. The phase 3 THOR trial compared the efficacy of erdafitinib to chemotherapy or immunotherapy in FGFR3/2-altered advanced UC. THOR offers valuable data informing sequencing strategies, reinforcing the need for molecular testing in UC.
科研通智能强力驱动
Strongly Powered by AbleSci AI